Evidence map›Paper›PMID 35399710›Full record

ArticleJournal of Cancer2022

Global Research Trends on the Treatment of Diffuse Large B-Cell Lymphoma: A Bibliometric and Visualized Study.

Qintong Duan, Yufeng Li, Lijia Ou, Yajun Li, Ruolan Zeng, Yizi He, Tao Pan, Siwei Chen, Huan Chen, Hui Zang and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Qintong DuanDepartment of Histology and Embryology of School of Basic Medical Sciences, Central South University, Changsha, Hunan, China.
Yufeng LiDepartment of Histology and Embryology of School of Basic Medical Sciences, Central South University, Changsha, Hunan, China.
Lijia OuDepartment of Histology and Embryology of School of Basic Medical Sciences, Central South University, Changsha, Hunan, China.
Yajun LiDepartment of Lymphoma & Hematology, The Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, Hunan, China.
Ruolan ZengDepartment of Lymphoma & Hematology, The Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, Hunan, China.
Yizi HeDepartment of Lymphoma & Hematology, The Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, Hunan, China.
Tao PanDepartment of Lymphoma & Hematology, The Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, Hunan, China.
Siwei ChenDepartment of Histology and Embryology of School of Basic Medical Sciences, Central South University, Changsha, Hunan, China.
Huan ChenDepartment of Pathology and Pathophysiology of School of Basic Medical Sciences, Hunan University of Medicine, HuaiHua 418000.
Hui ZangDepartment of Human Anatomy and Histoembryology of School of Basic Medical Sciences, Yiyang Medical College, Yiyang.
Hui ZhouDepartment of Lymphoma & Hematology, The Affiliated Tumor Hospital of Xiangya Medical School, Central South University, Changsha, Hunan, China.
Ling XiaoDepartment of Histology and Embryology of School of Basic Medical Sciences, Central South University, Changsha, Hunan, China.
Central South University · CNHunan Cancer Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. Treatment of DLBCL has improved greatly in recent decades, with thousands of papers published. We conducted a bibliometric analysis of the literature on DLBCL treatment, and discussed cooperation among authors, countries, and institutions, and identified research hotspots for DLBCL treatment. We searched the Web of Science Core Collection (WOSCC) using "Diffuse Large B Cell Lymphoma or DLBCL" and "Treatment or Therapy or Clinical Trial" as the subject terms, and analyzed the publication year, research direction, country/region, institution, author, source publication, distribution of funding institutions, and other conditions provided by the database. In addition, scientometrics software was used to analyze literature citations and cooperative publications. Bibliometric analyses were performed using https://bibliometric.com/app and VOSviewer. Network maps were generated to evaluate collaborations between different authors, countries, institutions, and keywords. A total of 7,255 studies on treatment of DLBCL were retrieved from the WOSCC on February 19, 2021. We found that the number of publications increased gradually from 1999 to 2021, and this trend was relatively stable in the past 3 years. The countries that produced the most publications were the United States, China, and Japan. Among institutions, University of Texas MD Anderson Cancer Center published the most manuscripts. Furthermore, the United States also had the most annual publications, citations, distribution of journal sources, and funding. Cooperative research between countries is also relatively important to treatment of DLBCL. Therapeutic regimens such as CHOP and R-CHOP, and immunotherapy (CAR-T, PD1/PDL1, and CAR-NK, etc.), have received increased attention. Bibliometric analysis of studies related to DLBCL treatment can help researchers and clinical workers quickly understand the hotspots and development trends in this field, and provide reference for the formulation of public health policies.

Indexed as

bibliometric analysisdiffuse large B-cell Lymphoma (DLBCL)research progresstreatmentVisualizedVOSviewer

Identifiers

PMID35399710
PMCPMC8990428
OpenAlexW4226180066

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.